Skip to main content

Together we are beating cancer

Donate now

Cancer Research UK makes key appointments to its governing council

The Cancer Research UK logo
by Cancer Research UK | News

18 September 2007

0 comments 0 comments

Cancer Research UK announced a number of appointments to its Council of Trustees today (Tuesday 18 September).

David Newbigging, the current Chairman, has been appointed for a further three year term from the expiry of his current term on 31 October 2007.

Dr Melanie Lee, a Trustee and Chairman of the Charity’s technology transfer subsidiary Cancer Research Technology (CRT), has been appointed Deputy Chairman of the Council in succession to Professor Sir David Carter who retired at the Annual General Meeting on 13 September 2007.

Dame Bridget Ogilvie, a Trustee and former Director of the Wellcome Trust has been appointed Chairman of the Charity’s Council Research Strategy Group, also succeeding Professor Sir David Carter.

Sir Kenneth Calman, Chancellor of the University of Glasgow and former Vice Chancellor of the University of Durham, was appointed to the Council of Trustees at the Annual General Meeting on 13 September 2007. Sir Kenneth is a renowned cancer expert and is former Chief Medical Officer at the Department of Health. He co-authored the Calman-Hine Report which led to an overhaul of cancer services in the UK.

David Newbigging said: “I’m honoured to have been appointed Chairman for a second three-year term. I’m also delighted that Dr Melanie Lee and Dame Bridget Ogilvie have been respectively appointed Deputy Chairman of Council and Chair of our Cancer Research Strategy Group in succession to Sir David Carter. They bring wide experience of scientific and medical research. We are also fortunate that Sir Kenneth Calman has agreed to join our Council and its Research Strategy Group.

“I should like to pay tribute to the immense contribution which Sir David Carter has made to Cancer Research UK. He was a Founding Trustee and we have been very fortunate to have had him on the Council during our formative years.”

ENDS

For more information contact the Cancer Research UK press office on 020 7061 8300.